ZA200802222B - Pyrimidine amide compounds as PGDS inhibitors - Google Patents

Pyrimidine amide compounds as PGDS inhibitors

Info

Publication number
ZA200802222B
ZA200802222B ZA200802222A ZA200802222A ZA200802222B ZA 200802222 B ZA200802222 B ZA 200802222B ZA 200802222 A ZA200802222 A ZA 200802222A ZA 200802222 A ZA200802222 A ZA 200802222A ZA 200802222 B ZA200802222 B ZA 200802222B
Authority
ZA
South Africa
Prior art keywords
amide compounds
pgds inhibitors
pyrimidine amide
pyrimidine
pgds
Prior art date
Application number
ZA200802222A
Other languages
English (en)
Inventor
Suzanne C Aldous
Lu Jinqi
Mu Lan
Sabol Jeffrey Stephen
Vandeusen Christopher Loren
Jiang John Ziqi
Ma Liang
Munson Harry Randall
Thurairatnam Sukanthini
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ZA200802222B publication Critical patent/ZA200802222B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200802222A 2005-10-04 2008-03-10 Pyrimidine amide compounds as PGDS inhibitors ZA200802222B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
ZA200802222B true ZA200802222B (en) 2009-09-30

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802222A ZA200802222B (en) 2005-10-04 2008-03-10 Pyrimidine amide compounds as PGDS inhibitors

Country Status (27)

Country Link
US (1) US8202863B2 (enExample)
EP (1) EP1937652B1 (enExample)
JP (1) JP5452925B2 (enExample)
KR (1) KR101457966B1 (enExample)
CN (2) CN101282943A (enExample)
AR (1) AR056871A1 (enExample)
AU (1) AU2006299428B2 (enExample)
BR (1) BRPI0616815A2 (enExample)
CA (1) CA2624749C (enExample)
CR (1) CR9832A (enExample)
DO (1) DOP2006000210A (enExample)
EC (1) ECSP088335A (enExample)
ES (1) ES2514471T3 (enExample)
IL (1) IL190411A (enExample)
MA (1) MA29925B1 (enExample)
MY (1) MY151172A (enExample)
NO (1) NO20082000L (enExample)
NZ (1) NZ567208A (enExample)
PE (2) PE20110118A1 (enExample)
RU (1) RU2420519C2 (enExample)
SG (1) SG166121A1 (enExample)
TN (1) TNSN08104A1 (enExample)
TW (1) TWI415839B (enExample)
UA (1) UA93213C2 (enExample)
UY (1) UY29840A1 (enExample)
WO (1) WO2007041634A1 (enExample)
ZA (1) ZA200802222B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566722A (en) * 2005-09-15 2010-11-26 Orchid Res Lab Ltd Novel pyrimidine carboxamides
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用
CA2679198C (en) * 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
ES2663517T3 (es) * 2007-08-27 2018-04-13 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos de isoxazol
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
JP5555169B2 (ja) * 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
AU2008310663A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
EP2215054B8 (en) * 2007-11-13 2012-02-08 Evotec AG Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
EP2286221A4 (en) * 2008-05-13 2011-07-06 Cayman Chem Co METHOD FOR TESTING COMPOUNDS OR MEANS FOR THEIR POSSIBILITY TO DISPLACE STRONG LIGANDS OF THE HEMATOPOIETIC PROSTAGLANDIN D-SYNTHASE
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
BRPI0919004A2 (pt) 2008-09-22 2019-09-24 Cayman Chem Co composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
AU2010222122B2 (en) 2009-03-09 2013-06-27 Taiho Pharmaceutical Co., Ltd. Piperazine compound capable of inhibiting prostaglandin D synthase
BR112012007635B1 (pt) * 2009-10-08 2019-07-09 Sanofi Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação
EP2527340B1 (en) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
US9199976B2 (en) 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2012033069A1 (ja) 2010-09-07 2012-03-15 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペリジン化合物
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CN104159587A (zh) 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EP3638672A1 (en) 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
US11357759B2 (en) 2017-10-29 2022-06-14 China Medical University Composition including ADAM9 inhibitor and the use thereof
EP3724197A1 (en) 2017-12-13 2020-10-21 GlaxoSmithKline Intellectual Property Development Ltd Fused pyridines which act as inhibitors of h-pgds
JP7428692B2 (ja) * 2018-03-23 2024-02-06 ステップ ファーマ エス.エー.エス Ctps1阻害剤としてのアミノピリミジン誘導体
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CA3182912A1 (en) * 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
US20230339937A1 (en) 2020-06-19 2023-10-26 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds
JP2023546996A (ja) * 2020-10-23 2023-11-08 ニンバス クロソー, インコーポレイテッド Ctps1阻害剤およびその使用
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
WO2023091456A1 (en) * 2021-11-17 2023-05-25 Chdi Foundation, Inc. N-(2h-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as htt modulators for the treatment of huntington's disease
EP4450502A4 (en) * 2021-12-17 2025-06-11 Sato Pharmaceutical Co., Ltd. AZAINDOLE DERIVATIVE INHIBITING H-PGDS
JPWO2023163140A1 (enExample) * 2022-02-28 2023-08-31

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
ATE450533T1 (de) 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
ES2257616T3 (es) * 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
WO2005032493A2 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
WO2005072681A2 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
AU2006299428B2 (en) 2012-04-26
MY151172A (en) 2014-04-30
UY29840A1 (es) 2007-05-31
JP2009510170A (ja) 2009-03-12
CR9832A (es) 2008-06-18
DOP2006000210A (es) 2007-06-15
KR20080050611A (ko) 2008-06-09
RU2008117170A (ru) 2009-11-10
IL190411A0 (en) 2008-11-03
EP1937652A1 (en) 2008-07-02
MA29925B1 (fr) 2008-11-03
WO2007041634A1 (en) 2007-04-12
CN101538246A (zh) 2009-09-23
AR056871A1 (es) 2007-10-31
TW200812977A (en) 2008-03-16
US20080227782A1 (en) 2008-09-18
NZ567208A (en) 2011-03-31
PE20070589A1 (es) 2007-06-22
EP1937652B1 (en) 2014-07-30
CN101538246B (zh) 2014-07-16
UA93213C2 (en) 2011-01-25
CN101282943A (zh) 2008-10-08
KR101457966B1 (ko) 2014-11-04
ECSP088335A (es) 2008-05-30
AU2006299428A1 (en) 2007-04-12
TWI415839B (zh) 2013-11-21
PE20110118A1 (es) 2011-03-08
JP5452925B2 (ja) 2014-03-26
IL190411A (en) 2013-09-30
US8202863B2 (en) 2012-06-19
SG166121A1 (en) 2010-11-29
TNSN08104A1 (en) 2009-07-14
NO20082000L (no) 2008-06-09
RU2420519C2 (ru) 2011-06-10
BRPI0616815A2 (pt) 2011-07-05
ES2514471T3 (es) 2014-10-28
CA2624749C (en) 2011-08-16
CA2624749A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
IL190411A0 (en) Pyrimidine amide compounds as pgds inhibitors
IL200898A0 (en) Pyrimidine hydrazide compounds as pgds inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
EP1954277A4 (en) AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
ZA200800379B (en) Glutamate aggrecanase inhibitors
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SI1910348T1 (sl) Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
IL186526A0 (en) Substituted amide derivatives as protein kinase inhibitors
IL190078A0 (en) Kinase inhibitors
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
PL1943243T3 (pl) Inhibitory kinazy
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
ZA200800672B (en) Introcatechol derivatives as COMT inhibitors
IL188474A0 (en) New salt i
ZA200804768B (en) Aminopyrimidines useful as kinase inhibitors
GB0516967D0 (en) Inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
GB0512626D0 (en) Inhibitor compounds
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors